Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investmentsCommercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEXManagement to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 10, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)...
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


